Company / R&D Expense
NRX Pharmaceuticals, Inc. R&D Expense History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$6.2M
FY2025
5-year range
$6.2M / $13.4M
FY2024-FY2025
Trend
-53.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$6M in FY2025.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense decreased 53.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -5.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2M | -53.6% |
| FY2024 | $13.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026